Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trialsAlexa B. Kimball, Elisa Muscianisi, Alice B. Gottlieb et al.|The Lancet|2023Cited by 318
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Alexa B. Kimball, Jacek C. Szepietowski et al.|Dermatology and Therapy|2025Cited by 2